Novovax CEO Stanley Erck speaks at a Coronavirus Task Force meeting in the Cabinet Room of the White House, Monday, March 2, 2020 (Andrew Harnik, AP Images)
May 11, 2020 04:02 PM EDTUpdated 04:57 PM
R&D
Coronavirus

CEPI bets $384M on No­vavax’s Covid-19 vac­cine — cov­er­ing R&D and man­u­fac­tur­ing in the ground­break­ing race to beat the pan­dem­ic

John Carroll

Editor & Founder

No­vavax $NVAX got some bad­ly need­ed seed cash from the Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions — CEPI — back in March that al­lowed them to get start­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times